Immutep Reports Positive Data from Soft Tissue Sarcoma Trial; Shares Up 5%

MT Newswires Live11-14 11:09

Biotechnology company Immutep (ASX:IMM) said its EFTISARC-NEO, a second phase trial of eftilagimod alpha in combination with radiotherapy and KEYTRUDA for patients with soft tissue sarcoma, showed positive data, according to a Thursday filing with the Australian bourse.

The triple combination therapy, based on a preliminary analysis of 21 patients, showed "significant" efficacy in the neoadjuvant setting for resectable soft tissue sarcoma, the filing said.

The study also found an over three-fold increase in tumor hyalinization, a crucial predictor of overall survival, compared with historical results from radiotherapy alone.

The EFTISARC-NEO study, led by the Maria Skłodowska-Curie National Research Institute of Oncology, is expected to enroll 40 patients in the first quarter of 2025, according to the filing.

The new data from the study was presented at the Connective Tissue Oncology Society annual meeting, the filing added.

Immutep shares rose nearly 5% in afternoon trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483292896?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-14 11:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483292896","market":"fut","top_or_hot":-1,"title":"Immutep Reports Positive Data from Soft Tissue Sarcoma Trial; Shares Up 5%","media":"MT Newswires Live","content":"<html><body><p> Biotechnology company Immutep (ASX:IMM) said its EFTISARC-NEO, a second phase trial of eftilagimod alpha in combination with radiotherapy and KEYTRUDA for patients with soft tissue sarcoma, showed positive data, according to a Thursday filing with the Australian bourse.</p><p>The triple combination therapy, based on a preliminary analysis of 21 patients, showed \"significant\" efficacy in the neoadjuvant setting for resectable soft tissue sarcoma, the filing said.</p><p>The study also found an over three-fold increase in tumor hyalinization, a crucial predictor of overall survival, compared with historical results from radiotherapy alone.</p><p>The EFTISARC-NEO study, led by the Maria Skłodowska-Curie National Research Institute of Oncology, is expected to enroll 40 patients in the first quarter of 2025, according to the filing.</p><p>The new data from the study was presented at the Connective Tissue Oncology Society annual meeting, the filing added.</p><p>Immutep shares rose nearly 5% in afternoon trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep Reports Positive Data from Soft Tissue Sarcoma Trial; Shares Up 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep Reports Positive Data from Soft Tissue Sarcoma Trial; Shares Up 5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 11:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotechnology company Immutep (ASX:IMM) said its EFTISARC-NEO, a second phase trial of eftilagimod alpha in combination with radiotherapy and KEYTRUDA for patients with soft tissue sarcoma, showed ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2483292896","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483292896","pubTimestamp":1731553761,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biotechnology company Immutep  said its EFTISARC-NEO, a second phase trial of eftilagimod alpha in combination with radiotherapy and KEYTRUDA for patients with soft tissue sarcoma, showed positive data, according to a Thursday filing with the Australian bourse.The triple combination therapy, based on a preliminary analysis of 21 patients, showed \"significant\" efficacy in the neoadjuvant setting for resectable soft tissue sarcoma, the filing said.The study also found an over three-fold increase in tumor hyalinization, a crucial predictor of overall survival, compared with historical results from radiotherapy alone.The EFTISARC-NEO study, led by the Maria Skodowska-Curie National Research Institute of Oncology, is expected to enroll 40 patients in the first quarter of 2025, according to the filing.The new data from the study was presented at the Connective Tissue Oncology Society annual meeting, the filing added.Immutep shares rose nearly 5% in afternoon trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","IMM.AU":"IMMUTEP LTD","BK7067":"生物科技"},"translate_title":"Immutep报告软组织肉瘤试验的积极数据；股价上涨5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":0.9},"content_text":"Biotechnology company Immutep (ASX:IMM) said its EFTISARC-NEO, a second phase trial of eftilagimod alpha in combination with radiotherapy and KEYTRUDA for patients with soft tissue sarcoma, showed positive data, according to a Thursday filing with the Australian bourse.The triple combination therapy, based on a preliminary analysis of 21 patients, showed \"significant\" efficacy in the neoadjuvant setting for resectable soft tissue sarcoma, the filing said.The study also found an over three-fold increase in tumor hyalinization, a crucial predictor of overall survival, compared with historical results from radiotherapy alone.The EFTISARC-NEO study, led by the Maria Skłodowska-Curie National Research Institute of Oncology, is expected to enroll 40 patients in the first quarter of 2025, according to the filing.The new data from the study was presented at the Connective Tissue Oncology Society annual meeting, the filing added.Immutep shares rose nearly 5% in afternoon trade.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483292896"}